BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15170977)

  • 1. [Chemotherapy].
    Aiba K
    Gan To Kagaku Ryoho; 2004 May; 31(5):706-11. PubMed ID: 15170977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [IFL].
    Yamazaki K; Yoshino T; Boku N
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress of chemotherapy for colorectal cancer].
    Ishiguro A; Shitara K; Munakata M; Saitoh S; Sakata Y
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2017-23. PubMed ID: 16352922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent advance in chemotherapy for advanced colorectal cancer].
    Aiba K
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of oxaliplatin in the management of colorectal cancer.
    de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
    Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
    Hwang JJ
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
    Carnaghi C; Zucali P; Garassino I
    Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of adjuvant therapy for colorectal cancer.
    O'Connell MJ
    Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.
    Recchia F; Rea S; Nuzzo A; Lalli A; Di Lullo L; De Filippis S; Saggio G; Di Blasio A; Massa E; Mantovani G
    Oncol Rep; 2003; 10(1):65-9. PubMed ID: 12469146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [FOLFIRI regimen for metastatic or recurrent colorectal cancer].
    Uemura N; Yamada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):904-6. PubMed ID: 16835477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
    Hwang JJ; Eisenberg SG; Marshall JL
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):37-43. PubMed ID: 14569847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
    Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
    J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
    Popov IP; Jelic SB; Matijasevic MM; Grbic B; Babic DR
    J Exp Clin Cancer Res; 2004 Sep; 23(3):395-401. PubMed ID: 15595627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer: chemotherapy treatment overview.
    Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controversy of treatment for advanced colorectal cancer--intermedisine].
    Sato A; Shimada K; Taguchi S
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1260-9. PubMed ID: 14518404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.